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OBJECTIVES: To monitor the therapy of high risk cardiovas-
cular patients enrolled into HOPE TOO trial in Slovakia and to
determine the prevalence of clinical signiﬁcant interactions in this
cohort in the third year of the investment. METHODS: Therapy
of 849 high-risk ischemic heart disease (IHD) patients (deﬁned
as age over 55yrs), symptomatic IHD [deﬁned as myocardial
infarction (MI), unstable angina pectoris (UAP)], stroke, periph-
eral vascular disease and diabetes mellitus (DM) with at least one
more risk factor (arterial hypertension or hypercholesterolemia
or smoking) was analysed during HOPE-TOO study enrollment
and during the second year visit. RESULTS: High risk cohort
aged 69.27 yrs (57–90) consisted of 79.9% pts with arterial
hypertension, of 62.5% with DM, of 45.6% pts with prior MI,
and of 17.7% pts with stroke. In third year of the trial partici-
pation average number of drugs was 6.57 (0–20) and 442
(60.47%) pts used more than 6 drugs. Clinically important inter-
actions (grade1,2) were presented in 241 (32.97%) pts. Most 
frequent interactions were with digoxin coprescribed with
furosemid—61 (8.34%) pts., digoxin-simvastatin—19pts.
(2.60%), digoxin-amilorid—16 (2.19%) pts. Average age in the
women’s group was 69.5yrs. Women took an average of 7.22
medications and the average interaction was 0.24. Average age
in the men’s group was 69.04yrs. Compared to the women, men
took only 5.96 drugs and the average interaction was 0.24.
CONCLUSION: High-risk cardiovascular patients are directly
endangered by polypragmacy and drug interactions even during
a three year follow up. Structure of their therapy must be care-
fully monitored.
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OBJECTIVES: To project the cumulative incidence of end-stage
renal disease (ESRD), life expectancy and costs in China of treat-
ing patients with diabetes, hypertension, and microalbuminuria
(DHM) with either standard hypertension treatment alone or
standard hypertension treatment plus irbesartan 300mg daily.
METHODS: A peer-reviewed Markov model that simulated pro-
gression from microalbuminuria to nephropathy, doubling of
serum creatinine, ESRD, and all-cause mortality in patients with
DHM was adapted to China. Three strategies were compared:
A) early use of irbesartan (i.e. start treatment in subjects with
microalbuminuria) versus B) late use of irebesartan (i.e. as from
overt nephropathy), or C) standard hypertension care (with com-
parable blood pressure control). Cumulative incidence of ESRD,
costs and life expectancy were projected for a hypothetical
cohort of 1000 subjects. Treatment-speciﬁc progression and
mortality probabilities were derived from published trials:
IRMA-2 (in microalbuminuria) and IDNT (in overt nephropa-
thy). Medical management and cost data per state were obtained
from published local sources. A ﬂexible time horizon up to 25
years and third party payer perspective were used. Future costs
and LE were discounted at 3% yearly. RESULTS: When com-
pared to standard blood pressure control, early irbesartan was
projected to reduce the cumulative incidence of ESRD from
(mean ± standard deviation) 22% to 8%, save RMB 30,348 (US
$3,667), and add 0.638 life years per treated patient. Late irbe-
sartan was dominant to control but dominated by early irbesar-
tan. The superiority of early use of irbesartan over standard care
was robust for most variables, except for the cost of dialysis and
the time horizon. Break-even occurred after 13 years. CON-
CLUSIONS: Treating DHM patients with early irbesartan was
projected to reduce the incidence of ESRD, extend life and reduce
costs. Treating patients at a later stage is still beneﬁcial, however
to a lower extent. Applying ﬂexible time horizons shows addi-
tional relevant information to decision makers.
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OBJECTIVE: Patients with acute coronary syndrome without
ST-segment elevation receiving Clopidogrel in addition to acetyl-
salicylic acid (ASS) showed 20% risk reduction in the CURE
trial. Economic models for assessing the impact on costs exist
for several countries, however not for Germany on a long-term
basis. The objective of this model adaptation is to assess the long-
term economic impact of Clopidogrel taken in addition to ASS
in Germany. METHODS: A Markov model with six states (at
risk, ﬁrst year with stroke, following years with stroke, ﬁrst year
with new myocardial infarction (MI), following years with MI
and death) was adapted for Germany. Model outcome was life-
years saved. Cost and effects of one year treatment were calcu-
lated based on the CURE trial. Resource use for the different
health states during follow-up were based on desk research or
on expert opinion, which included costs for drugs, physician
visits, hospitalisation, rehabilitation and nursing. Risk data for
MI and stroke were based on Swedish data. The model calclu-
lates life-time costs and survival length. Costs were estimated
from the payers’l perspective within the German health care
system. Sensitivity analysis varied follow-up treatment costs at 
-50% and +100%. RESULTS: The Markov analysis resulted in
8.89 life-years saved for the placebo treatment group and 9.02
for the Clopidogrel® treatment group. The cumulated cost were
9288 and 9653 resp. The incremental cost effectiveness ratio
(ICER) was 2670€ for each life-years saved. In the sensitivity
analysis halving of follow-up cost lead to an ICER at 3666€ and
doubling to 677€. CONCLUSION: Our results are in line with
results in other Health Care systems. Adding Clopidogrel in
addition to ASS for patients with acute coronary syndrome
without ST-segment elevation generates an additional life-year
saved at a comparably low value of 2670€ in Germany.
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